Benzinga | May 11, 2021 08:45AM EDT

SVB Leerink Initiates Coverage On Recursion Pharmaceuticals with Outperform Rating, Announces Price Target of $33

SVB Leerink analyst Mani Foroohar initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Outperform rating and announces Price Target of $33.